(Q41069257)

26 September 2017

Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska (English)

1 reference

pneumococcal conjugate vaccine

26 September 2017

1 reference

1 reference

9

Thomas Hennessy

1 reference

26 September 2017

8

Dana Bruden

1 reference

26 September 2017

1

Michael G Bruce

1 reference

26 September 2017

2

Rosalyn Singleton

1 reference

26 September 2017

3

Lisa Bulkow

1 reference

26 September 2017

7

Debby Hurlburt

1 reference

26 September 2017

4

Karen Rudolph

1 reference

26 September 2017

6

Prabhu Gounder

1 reference

26 September 2017

5

Tammy Zulz

1 reference

PubMed ID

26247901

26 September 2017

language of work or name

English

0 references

publication date

3 August 2015

1 reference

26 September 2017

1 reference

26 September 2017

33

1 reference

26 September 2017

38

1 reference

26 September 2017

4813-4819

1 reference

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Evaluation of a volunteer sample in nasopharyngeal colonization surveys for Streptococcus pneumoniae in rural Alaska.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--Alaska, 2008-2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Serotyping of Streptococcus pneumoniae isolates from nasopharyngeal samples: use of an algorithm combining microbiologic, serologic, and sequential multiplex PCR techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Molecular characterization of Streptococcus pneumoniae serotype 12F isolates associated with rural community outbreaks in Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.080

10.1016/J.VACCINE.2015.07.080

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

26247901